Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer

By            

Oncology Reports, Vol. 29, Iss. 3, 2013-01 ,pp. : 951-959

Spandidos Publications

Access to resources Recommend Favorite

Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen

By Raderer M.   Kornek G.V.   Hejna M.H.L.   Miholic J.   Weinlaender G.   Brodowicz T.   Fiebiger W.C.C.   Valencak J.B.   Scheithauer W.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1128-1130

Elsevier

Access to resources Recommend Favorite

Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

By van Poznak C.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 3, 2001-04 ,pp. : 239-248

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer

By Goto Ayumu   Yamada Yasuhide   Hosokawa Ayumu   Ura Takashi   Arai Tatsuhiro   Hamaguchi Tetsuya   Muro Kei   Shimada Yasuhiro   Shirao Kuniaki  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 364-368

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite